TISIDB

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Note=Exclusively nuclear during interphase (PubMed:1312467). Detected in the nucleus and the cytoplasm at prophase (PubMed:1312467). Cytoplasmic when associated with SCAPER (PubMed:17698606).
Domain	PF02984 Cyclin PF00134 Cyclin PF16500 N-terminal region of cyclin_N
Function	Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000086 G2/M transition of mitotic cell cycle GO:0000302 response to reactive oxygen species GO:0001666 response to hypoxia GO:0006979 response to oxidative stress GO:0007067 mitotic nuclear division GO:0007093 mitotic cell cycle checkpoint GO:0007095 mitotic G2 DNA damage checkpoint GO:0007265 Ras protein signal transduction GO:0007346 regulation of mitotic cell cycle GO:0007423 sensory organ development GO:0010035 response to inorganic substance GO:0010389 regulation of G2/M transition of mitotic cell cycle GO:0010948 negative regulation of cell cycle process GO:0010972 negative regulation of G2/M transition of mitotic cell cycle GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031570 DNA integrity checkpoint GO:0031572 G2 DNA damage checkpoint GO:0032355 response to estradiol GO:0033762 response to glucagon GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0034698 response to gonadotropin GO:0034699 response to luteinizing hormone GO:0036119 response to platelet-derived growth factor GO:0036120 cellular response to platelet-derived growth factor stimulus GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0042220 response to cocaine GO:0043279 response to alkaloid GO:0043434 response to peptide hormone GO:0043583 ear development GO:0044320 cellular response to leptin stimulus GO:0044321 response to leptin GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044818 mitotic G2/M transition checkpoint GO:0044839 cell cycle G2/M phase transition GO:0045786 negative regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0048144 fibroblast proliferation GO:0048145 regulation of fibroblast proliferation GO:0048146 positive regulation of fibroblast proliferation GO:0048839 inner ear development GO:0070482 response to oxygen levels GO:0071241 cellular response to inorganic substance GO:0071312 cellular response to alkaloid GO:0071314 cellular response to cocaine GO:0071371 cellular response to gonadotropin stimulus GO:0071373 cellular response to luteinizing hormone stimulus GO:0071375 cellular response to peptide hormone stimulus GO:0071392 cellular response to estradiol stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071731 response to nitric oxide GO:0071732 cellular response to nitric oxide GO:0071900 regulation of protein serine/threonine kinase activity GO:0090102 cochlea development GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902170 cellular response to reactive nitrogen species GO:1902749 regulation of cell cycle G2/M phase transition GO:1902750 negative regulation of cell cycle G2/M phase transition GO:1904029 regulation of cyclin-dependent protein kinase activity GO:1990314 cellular response to insulin-like growth factor stimulus
Molecular Function	-
Cellular Component	GO:0001939 female pronucleus GO:0001940 male pronucleus GO:0045120 pronucleus

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle hsa04152 AMPK signaling pathway hsa04914 Progesterone-mediated oocyte maturation
Reactome	R-HSA-174143: APC/C-mediated degradation of cell cycle proteins R-HSA-176409: APC/C R-HSA-179419: APC R-HSA-176814: Activation of APC/C and APC/C R-HSA-174184: Cdc20 R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-69278: Cell Cycle, Mitotic R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-69273: Cyclin A/B1 associated events during G2/M transition R-HSA-69656: Cyclin A R-HSA-69202: Cyclin E associated events during G1/S transition R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-69306: DNA Replication R-HSA-5688426: Deubiquitination R-HSA-1538133: G0 and Early G1 R-HSA-69615: G1/S DNA Damage Checkpoints R-HSA-69206: G1/S Transition R-HSA-68911: G2 Phase R-HSA-69275: G2/M Transition R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) R-HSA-5693538: Homology Directed Repair R-HSA-392499: Metabolism of proteins R-HSA-453279: Mitotic G1-G1/S phases R-HSA-453274: Mitotic G2-G2/M phases R-HSA-68949: Orc1 removal from chromatin R-HSA-170145: Phosphorylation of proteins involved in the G2/M transition by Cyclin A R-HSA-597592: Post-translational protein modification R-HSA-5693607: Processing of DNA double-strand break ends R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase R-HSA-69304: Regulation of DNA replication R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-6804757: Regulation of TP53 Degradation R-HSA-6806003: Regulation of TP53 Expression and Degradation R-HSA-453276: Regulation of mitotic cell cycle R-HSA-69300: Removal of licensing factors from origins R-HSA-69242: S Phase R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21 R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP) R-HSA-69052: Switching of origins to a post-replicative state R-HSA-69239: Synthesis of DNA R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-5689880: Ub-specific processing proteases R-HSA-69563: p53-Dependent G1 DNA Damage Response R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle
hsa04152 AMPK signaling pathway
hsa04914 Progesterone-mediated oocyte maturation

Reactome

R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-176409: APC/C
R-HSA-179419: APC
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-174184: Cdc20
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69273: Cyclin A/B1 associated events during G2/M transition
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-69306: DNA Replication
R-HSA-5688426: Deubiquitination
R-HSA-1538133: G0 and Early G1
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-69206: G1/S Transition
R-HSA-68911: G2 Phase
R-HSA-69275: G2/M Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5693538: Homology Directed Repair
R-HSA-392499: Metabolism of proteins
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-68949: Orc1 removal from chromatin
R-HSA-170145: Phosphorylation of proteins involved in the G2/M transition by Cyclin A
R-HSA-597592: Post-translational protein modification
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-69304: Regulation of DNA replication
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-5689880: Ub-specific processing proteases
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCNA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCNA2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.12; FDR: 0.03500	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCNA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.147	0.665
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.09	0.955
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.189	0.876
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.293	0.567
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.227	0.869
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.385	0.837
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.231	0.543
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.469	0.735
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.125	0.929
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.361	0.662
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.708	0.571
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.525	1.67e-05

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCNA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCNA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCNA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCNA2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCNA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCNA2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCNA2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCNA2
Name	cyclin A2
Aliases	CCNA; cyclin-A; Cyclin-A2
Chromosomal Location	4q27
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCNA2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CCNA2.

ID	Name	Drug Type	Targets	#Targets
DB02091	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	Small Molecule	CCNA2, CDK2	2
DB02407	6-O-Cyclohexylmethyl Guanine	Small Molecule	CCNA2, CDK2	2
DB02833	[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine	Small Molecule	CCNA2, CDK2	2
DB02915	4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine	Small Molecule	CCNA2, CDK2	2
DB06844	4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB06944	N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide	Small Molecule	CCNA2, CDK2	2
DB06948	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	Small Molecule	CCNA2, CDK2	2
DB07126	O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE	Small Molecule	CCNA2, CDK2	2
DB07137	(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE	Small Molecule	CCNA2, CDK2	2
DB07164	N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	Small Molecule	CCNA2, CDK2	2
DB07203	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	Small Molecule	CCNA2, CDK2	2
DB07471	5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE	Small Molecule	CCNA2, CDK2	2
DB07533	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB07534	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB07538	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB07539	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID	Small Molecule	CCNA2, CDK2	2
DB07562	N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE	Small Molecule	CCNA2, CDK2	2
DB07688	4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB07852	1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID	Small Molecule	CCNA2, CDK2	2
DB08178	4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	Small Molecule	CCNA2, CDK2	2
DB08182	4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	Small Molecule	CCNA2, CDK2	2
DB08218	HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM	Small Molecule	CCNA2, CDK2	2
DB08219	4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE	Small Molecule	CCNA2, CDK2	2
DB08233	6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE	Small Molecule	CCNA2, CDK2	2
DB08241	4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE	Small Molecule	CCNA2, CDK2	2
DB08248	3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE	Small Molecule	CCNA2, CDK2	2
DB08285	(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol	Small Molecule	CCNA2, CDK2	2
DB08309	3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL	Small Molecule	CCNA2, CDK2	2
DB08355	1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid	Small Molecule	CCNA2, CDK2	2
DB08463	(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol	Small Molecule	CCNA2, CDK2	2
DB08527	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	Small Molecule	CCNA2, CDK2	2
DB08572	4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE	Small Molecule	CCNA2, CDK2	2
DB08694	9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol	Small Molecule	CCNA2, CDK2	2

Browse CCNA2